ArticleBrain sciences2021

A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy.

Gian Luca Vita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.